[
  {
    "ts": null,
    "headline": "HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y",
    "summary": "HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.",
    "url": "https://finnhub.io/api/news?id=b3147d27fa0a8e950bf133dac47b734f89ac87463e0d7c071ecc99772e8ecb17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756923780,
      "headline": "HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y",
      "id": 136642128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.",
      "url": "https://finnhub.io/api/news?id=b3147d27fa0a8e950bf133dac47b734f89ac87463e0d7c071ecc99772e8ecb17"
    }
  },
  {
    "ts": null,
    "headline": "Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=d537f607b6f00480a1a96275b02548099b554faaf0c4e2c37b3bc939f3198ae7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756909802,
      "headline": "Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 136616955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=d537f607b6f00480a1a96275b02548099b554faaf0c4e2c37b3bc939f3198ae7"
    }
  },
  {
    "ts": null,
    "headline": "STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep",
    "summary": "Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.",
    "url": "https://finnhub.io/api/news?id=ad955c65f0745bb4cb2c685ad69d9c07c39592c515bf4cc4e16be7f8be349494",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756907400,
      "headline": "STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep",
      "id": 136616118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.",
      "url": "https://finnhub.io/api/news?id=ad955c65f0745bb4cb2c685ad69d9c07c39592c515bf4cc4e16be7f8be349494"
    }
  },
  {
    "ts": null,
    "headline": "Is Boston Scientific Stock Outperforming the S&P 500?",
    "summary": "As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=381dcda1265328db340aea5678eb93a53a94e8b7e5c455995c930cbf31b8b66c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756892122,
      "headline": "Is Boston Scientific Stock Outperforming the S&P 500?",
      "id": 136615761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=381dcda1265328db340aea5678eb93a53a94e8b7e5c455995c930cbf31b8b66c"
    }
  },
  {
    "ts": null,
    "headline": "Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment",
    "summary": "Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciencesAllegro prepares to advance lead product hydrocelin into clinical trials in 2026 Liege, Belgium – 3 September 2025 (08:30) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has appointed Stephan Crokaert into the role of Chief Operating Officer as of this month.",
    "url": "https://finnhub.io/api/news?id=69d0083780d812ec107ef9f5ff420f471cbff657bdc8bd4daf6e8c75fb933afa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756884600,
      "headline": "Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment",
      "id": 136613012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciencesAllegro prepares to advance lead product hydrocelin into clinical trials in 2026 Liege, Belgium – 3 September 2025 (08:30) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has appointed Stephan Crokaert into the role of Chief Operating Officer as of this month.",
      "url": "https://finnhub.io/api/news?id=69d0083780d812ec107ef9f5ff420f471cbff657bdc8bd4daf6e8c75fb933afa"
    }
  },
  {
    "ts": null,
    "headline": "DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment",
    "summary": "DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs.",
    "url": "https://finnhub.io/api/news?id=9df4b043bd694273b197e41768d2616baf76e3731c5736e0092fccd8e48e69f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756871520,
      "headline": "DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment",
      "id": 136613175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs.",
      "url": "https://finnhub.io/api/news?id=9df4b043bd694273b197e41768d2616baf76e3731c5736e0092fccd8e48e69f8"
    }
  }
]